These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 15474134)

  • 1. Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trial.
    Roberts I; Yates D; Sandercock P; Farrell B; Wasserberg J; Lomas G; Cottingham R; Svoboda P; Brayley N; Mazairac G; Laloë V; Muñoz-Sánchez A; Arango M; Hartzenberg B; Khamis H; Yutthakasemsunt S; Komolafe E; Olldashi F; Yadav Y; Murillo-Cabezas F; Shakur H; Edwards P;
    Lancet; 2004 Oct 9-15; 364(9442):1321-8. PubMed ID: 15474134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6 months.
    Edwards P; Arango M; Balica L; Cottingham R; El-Sayed H; Farrell B; Fernandes J; Gogichaisvili T; Golden N; Hartzenberg B; Husain M; Ulloa MI; Jerbi Z; Khamis H; Komolafe E; Laloë V; Lomas G; Ludwig S; Mazairac G; Muñoz Sanchéz Mde L; Nasi L; Olldashi F; Plunkett P; Roberts I; Sandercock P; Shakur H; Soler C; Stocker R; Svoboda P; Trenkler S; Venkataramana NK; Wasserberg J; Yates D; Yutthakasemsunt S;
    Lancet; 2005 Jun 4-10; 365(9475):1957-9. PubMed ID: 15936423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corticosteroid use in head injuries.
    Wadia RS
    Natl Med J India; 2005; 18(1):25. PubMed ID: 15835488
    [No Abstract]   [Full Text] [Related]  

  • 4. The MRC CRASH Trial: study design, baseline data, and outcome in 1000 randomised patients in the pilot phase.
    Edwards P; Farrell B; Lomas G; Mashru R; Ritchie N; Roberts I; Sandercock P; Wasserberg J; Yates D;
    Emerg Med J; 2002 Nov; 19(6):510-4. PubMed ID: 12421773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The MRC CRASH trial--a large, simple randomised trial of steroids in head injury.
    Wasserberg J;
    Acta Neurochir Suppl; 2004; 89():109-12. PubMed ID: 15335109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial.
    Le Page E; Veillard D; Laplaud DA; Hamonic S; Wardi R; Lebrun C; Zagnoli F; Wiertlewski S; Deburghgraeve V; Coustans M; Edan G; ;
    Lancet; 2015 Sep; 386(9997):974-81. PubMed ID: 26135706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 12-h pretreatment with methylprednisolone versus placebo for prevention of postextubation laryngeal oedema: a randomised double-blind trial.
    François B; Bellissant E; Gissot V; Desachy A; Normand S; Boulain T; Brenet O; Preux PM; Vignon P;
    Lancet; 2007 Mar; 369(9567):1083-9. PubMed ID: 17398307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Magnesium sulfate for neuroprotection after traumatic brain injury: a randomised controlled trial.
    Temkin NR; Anderson GD; Winn HR; Ellenbogen RG; Britz GW; Schuster J; Lucas T; Newell DW; Mansfield PN; Machamer JE; Barber J; Dikmen SS
    Lancet Neurol; 2007 Jan; 6(1):29-38. PubMed ID: 17166799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Possible explanations for the results of CRASH.
    Peto R
    Lancet; 2005 Jan 15-21; 365(9455):213; author reply 213-214. PubMed ID: 15652598
    [No Abstract]   [Full Text] [Related]  

  • 10. Hydrocortisone and fludrocortisone for prevention of hospital-acquired pneumonia in patients with severe traumatic brain injury (Corti-TC): a double-blind, multicentre phase 3, randomised placebo-controlled trial.
    Asehnoune K; Seguin P; Allary J; Feuillet F; Lasocki S; Cook F; Floch H; Chabanne R; Geeraerts T; Roger C; Perrigault PF; Hanouz JL; Lukaszewicz AC; Biais M; Boucheix P; Dahyot-Fizelier C; Capdevila X; Mahe PJ; Le Maguet P; Paugam-Burtz C; Gergaud S; Plaud B; Constantin JM; Malledant Y; Flet L; Sebille V; Roquilly A;
    Lancet Respir Med; 2014 Sep; 2(9):706-16. PubMed ID: 25066331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A CRASH landing in severe head injury.
    Sauerland S; Maegele M
    Lancet; 2004 Oct 9-15; 364(9442):1291-2. PubMed ID: 15474118
    [No Abstract]   [Full Text] [Related]  

  • 12. Possible explanations for the results of CRASH.
    Douglas IS
    Lancet; 2005 Jan 15-21; 365(9455):212; author reply 213-214. PubMed ID: 15652596
    [No Abstract]   [Full Text] [Related]  

  • 13. Erythropoietin in traumatic brain injury (EPO-TBI): a double-blind randomised controlled trial.
    Nichol A; French C; Little L; Haddad S; Presneill J; Arabi Y; Bailey M; Cooper DJ; Duranteau J; Huet O; Mak A; McArthur C; Pettilä V; Skrifvars M; Vallance S; Varma D; Wills J; Bellomo R; ;
    Lancet; 2015 Dec; 386(10012):2499-506. PubMed ID: 26452709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the Canadian CT Head Rule and the New Orleans Criteria in patients with minor head injury.
    Stiell IG; Clement CM; Rowe BH; Schull MJ; Brison R; Cass D; Eisenhauer MA; McKnight RD; Bandiera G; Holroyd B; Lee JS; Dreyer J; Worthington JR; Reardon M; Greenberg G; Lesiuk H; MacPhail I; Wells GA
    JAMA; 2005 Sep; 294(12):1511-8. PubMed ID: 16189364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
    Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
    Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter trial on the efficacy of using tirilazad mesylate in cases of head injury.
    Marshall LF; Maas AI; Marshall SB; Bricolo A; Fearnside M; Iannotti F; Klauber MR; Lagarrigue J; Lobato R; Persson L; Pickard JD; Piek J; Servadei F; Wellis GN; Morris GF; Means ED; Musch B
    J Neurosurg; 1998 Oct; 89(4):519-25. PubMed ID: 9761043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
    Sorensen PS; Mellgren SI; Svenningsson A; Elovaara I; Frederiksen JL; Beiske AG; Myhr KM; Søgaard LV; Olsen IC; Sandberg-Wollheim M
    Lancet Neurol; 2009 Jun; 8(6):519-29. PubMed ID: 19409854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Possible explanations for the results of CRASH.
    Kasperlik-Zaluska AA; Slowi'nska-Srzednicka J; Bonicki W; Kunicki J
    Lancet; 2005 Jan 15-21; 365(9455):212-3; author reply 213-214. PubMed ID: 15652595
    [No Abstract]   [Full Text] [Related]  

  • 19. Update on progress in the international, multicenter, randomized, controlled trial of corticosteroids after significant head injury (Medical Research Council CRASH Trial).
    MRC CRASH Trial National Coordinators
    Curr Opin Crit Care; 2003 Apr; 9(2):92-7. PubMed ID: 12657970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial.
    Maas AI; Murray G; Henney H; Kassem N; Legrand V; Mangelus M; Muizelaar JP; Stocchetti N; Knoller N;
    Lancet Neurol; 2006 Jan; 5(1):38-45. PubMed ID: 16361021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.